TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02640794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Study: NCT00824317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: (15 mg daily), medium (25 mg daily) and high (40 mg daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00985348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Keppra)
Description: Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Keppra)
Description: Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose
Study: NCT01068327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT04110392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chaya (Cnidoscolus chayamansa)
Description: Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
Study: NCT00864604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabumetone 750 mg tablets, single dose
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabumetone 750 mg tablets, single dose
Description: B: Active comparator Subjects received Teva formulated products under fed conditions
Study: NCT00168766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (Avonex) plus methylprednisolone
Description: oral administration given on 3 consecutive days, monthly as described in protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta-1a (Avonex) plus methylprednisolone
Description: oral administration given on 3 consecutive days, monthly as described in protocol.
Study: NCT00323362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400 mg/day orally, given Days 1-5 and 8-12 every 21 days
Study: NCT03113201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations-Liaison
Description: Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
Study: NCT01607398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADOAIR250
Description: 250 mcg inhalation, twice daily, from week0 -12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation, twice daily, from week0 -12.
Study: NCT02135276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eravacycline
Description: All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eravacycline
Description: All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
Study: NCT02633462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing , Myo-inositol
Description: scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol
Description: only provided treatment with Myo-inositol supplementation (1 gm twice a day)
Study: NCT02086968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectafer
Description: 2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325mg (1 tablet) three times a day for 28 days
Study: NCT03280628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Sutures
Description: The patient's doctor will close the patient's laceration with absorbable sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steri-Strips
Description: The patient's doctor will close the patient's laceration with Steri-Strips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: The patient's doctor will close the patient's laceration with Dermabond.
Study: NCT04619134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCSR Program
Description: flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: hot pack,flexibility training,strengthening exercise.
Study: NCT03936946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Content 1
Description: \~30 minute daily audio recordings of content 1 for 28 days

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio Content 1
Description: \~30 minute daily audio recordings of content 1 for 28 days

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Audio Content 2
Description: \~30 minute daily audio recordings of content 2 for 28 days
Study: NCT02253199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.
Study: NCT00564486

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV, every 6 hours for 24 hours (4 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV, every 4 hours for 24 hours (6 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV, every 6 hours for 24 hours (4 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV, every 4 hours for 24 hours (6 doses total)
Study: NCT00552812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent therapy of aortic coarctation
Description: Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
Study: NCT02454699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX400
Description: MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX400
Description: MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX400
Description: MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX400
Description: MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
Study: NCT03024359

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extra virgin olive oil
Description: 2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extra virgin olive oil
Description: 2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
Study: NCT04361006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency (RF)
Description: Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (CRYO)
Description: Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
Study: NCT01308762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat killed whole cell M. obuense (IMM-101) 0.1 mg
Description: Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat-killed whole cell M.obuense (IMM-101) 0.5 mg
Description: Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat killed whole cell M.obuense (IMM-101) 1.0 mg
Description: Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
Study: NCT00596973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Ileal transposition with sleeve gastrectomy
Study: NCT03458910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV training
Description: Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV training
Description: Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
Study: NCT03232775

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment: Physical Exam with Visual Pedagogy and Structure
Description: Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).

Intervention type: OTHER
Group type: OTHER
Intervention: Control: Physical Exam without Visual Pedagogy and Structure
Description: Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
Study: NCT00962013

Intervention type: DEVICE
Group type: OTHER
Intervention: Restoration® Modular Revision Hip System
Description: Restoration® Modular Revision System
Study: NCT01132170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg
Study: NCT00359359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
Study: NCT02406937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral intake of Feihe New Formula
Description: Oral intake of Feihe New Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral intake of Feihe Stage 1 Formula
Description: Oral intake of Feihe Stage 1 Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Breast Feeding
Description: Oral intake of breast milk
Study: NCT04125160

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring over 16 days

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring over 16 days

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycaemic markers
Description: Measurement of HbA1c, glycated albumin and fructosamine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycaemic markers
Description: Measurement of HbA1c, glycated albumin and fructosamine.
Study: NCT03480165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib 20 MG/ML
Description: 1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
Study: NCT02755727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injection
Description: See Arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgical Release
Description: See arms
Study: NCT02959372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung ultrasound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lung ultrasound. The attending physician will not know the result
Study: NCT01264328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab + paclitaxel
Description: Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
Study: NCT03763539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy
Study: NCT00301925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT01068327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo radiotherapy
Study: NCT00301925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT04551859

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Pelvic Floor MRI
Description: 6 months after surgery, a Dynamic Pelvic Floor MRI is performed
Study: NCT00967707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin and venlafaxine
Description: Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin and donepezil
Description: Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added.
Study: NCT03985800

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEAM
Description: TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TECH
Description: TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
Study: NCT03065517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VillageWhere App
Description: VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Attention-Control Placebo App
Description: Mobile phone app for use on both Android and iOS platforms.
Study: NCT04344782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.